tbuckley/cabot-search huggingface dataset:
Association between socioeconomic status and the development of mental and physical health conditions in adulthood: a multi-cohort study
Authors: Mika Kivimäki, G David Batty, Jaana Pentti, Martin J Shipley, Pyry N Sipilä, Solja T Nyberg, Sakari B Suominen, Tuula Oksanen, Sari Stenholm, Marianna Virtanen, Michael G Marmot, Archana Singh-Manoux, Eric J Brunner, Joni V Lindbohm, Jane E Ferrie, Jussi Vahtera
Journal: The Lancet Public Health (2020)

Socioeconomic disadvantage is a risk factor for many diseases. We characterised cascades of these conditions by using a data-driven approach to examine the association between socioeconomic status and temporal sequences in the development of 56 common diseases and health conditions.In this multi-cohort study, we used data from two Finnish prospective cohort studies: the Health and Social Support study and the Finnish Public Sector study. Our pooled prospective primary analysis data comprised 109 246 Finnish adults aged 17-77 years at study entry. We captured socioeconomic status using area deprivation and education at baseline (1998-2013). Participants were followed up for health conditions diagnosed according to the WHO International Classification of Diseases until 2016 using linkage to national health records. We tested the generalisability of our findings with an independent UK cohort study-the Whitehall II study (9838 people, baseline in 1997, follow-up to 2017)-using a further socioeconomic status indicator, occupational position.During 1 110 831 person-years at risk, we recorded 245 573 hospitalisations in the Finnish cohorts; the corresponding numbers in the UK study were 60 946 hospitalisations in 186 572 person-years. Across the three socioeconomic position indicators and after adjustment for lifestyle factors, compared with more advantaged groups, low socioeconomic status was associated with increased risk for 18 (32·1%) of the 56 conditions. 16 diseases formed a cascade of inter-related health conditions with a hazard ratio greater than 5. This sequence began with psychiatric disorders, substance abuse, and self-harm, which were associated with later liver and renal diseases, ischaemic heart disease, cerebral infarction, chronic obstructive bronchitis, lung cancer, and dementia.Our findings highlight the importance of mental health and behavioural problems in setting in motion the development of a range of socioeconomically patterned physical illnesses. Policy and health-care practice addressing psychological health issues in social context and early in the life course could be effective strategies for reducing health inequalities.UK Medical Research Council, US National Institute on Aging, NordForsk, British Heart Foundation, Academy of Finland, and Helsinki Institute of Life Science.
Gastrointestinal bleeding after endoscopic ultrasound-guided gallbladder drainage
Authors: Erica On Ting Chan, Shannon Melissa Chan, Hon Chi Yip, Anthony Yuen Bun Teoh
Journal: Endoscopy (2020)

Endoscopic ultrasound (EUS)-guided gallbladder drainage (EGBD) is gaining popularity as an option for the treatment of acute cholecystitis in patients who would be considered high risk for cholecystectomy [1]. EGBD has been shown to be associated with comparable technical and clinical success rates to percutaneous cholecystostomy, whilst carrying a 4.8 % – 22 % risk of adverse events, including pneumoperitoneum, bile leak, and stent migration [2] [3] [4] [5]. Stent-induced bleeding after EGBD is however uncommon.
Abstract 272: miRNA-7 Leads to Enhanced Fibrosis in the Heart
Authors: Manveen Gupta, Xi Wang, Elizabeth Martelli, Prasad Sathyamangla
Journal: Circulation Research (2016)

MicroRNA-7 (miR-7) is known to target epidermal growth factor receptors (EGFRs) in oncogenic cells however, less is known about its role and function in the heart. Our studies have identified reciprocal expression pattern for ERBB2 (a member of EGFR family) in the context of miR-7 expression in human heart failure and in mice post-TAC (Transverse Aortic Constriction). To directly determine the role of miR-7 in the heart, we generated transgenic (Tg) mice with cardiomyocyte-specific overexpression of miR-7 (miR-7 Tg). miR-7 Tg mice are characterized by marked loss in ERBB2 expression compared to their wildtype littermate controls. Also, miR-7 Tg mice have age-dependent deterioration in cardiac dysfunction and is associated with dilation as measured by echocardiography (3 months - 60% FS, 6 month -52% FS and 12 months - 24%FS) and yet, they survive over 18 months as assessed by Kaplan-Meier curves. To investigate whether pathological stress would accelerate the deterioration in cardiac function, miR-7 Tg mice were subjected to TAC for two weeks. In contrast to the wild type littermates that showed significant hypertrophic response, miR-7 Tg mice have accelerated cardiac dysfunction and dilation following two weeks of TAC. Histological analysis shows increased collagen deposition in miR-7 Tg mice which is further accelerated following after TAC compared to their sham controls. These observations suggest that ERBB2 expression in the cardiomyocytes may play a critical role in delaying the pro-fibrotic response post-TAC by supporting an adaptive hypertrophic response in response to stress. Our study will discuss the mechanisms of increased fibrosis observed in miR-7 Tg mice subjected to TAC.
GONO‐FOLFOXIRIプラスベバシズマブで治療した転移性大腸癌患者における循環プロ‐および抗‐血管新生因子の予備的分析
Authors: Cremolini C, Loupakis F, Salvatore L, Fioravanti A, Schirripa M, Orlandi P, Masi G, Di Desidero T, Fornaro L, Canu B, Baldi G, Stasi I, Danesi R, Bocci G, Falcone A
Journal: Annals of Oncology (2010)
Wuhan: Britons to be evacuated as scientists estimate 44 000 cases of 2019-nCOV in the city
Authors: Jane Parry
Journal: BMJ (2020)

The UK government has announced plans to fly hundreds of British citizens back from Wuhan, the epicentre of the 2019-nCOV outbreak, and to quarantine them for two weeks. The move comes after British Airways suspended all flights to and from mainland China until at least 31 January. Other countries, including Australia, Japan, and the United States have also started to repatriate citizens.

Scientists at the University of Hong Kong have estimated that the likely extent of infections in the …
Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable
Authors: Jonah Rubin, Mathew S. Maurer
Journal: Annual Review of Medicine (2020)

Cardiac amyloidosis (CA) is an infiltrative and restrictive cardiomyopathy that leads to heart failure, reduced quality of life, and death. The disease has two main subtypes, transthyretin cardiac amyloidosis (ATTR-CA) and immunoglobulin light chain cardiac amyloidosis (AL-CA), characterized by the nature of the infiltrating protein. ATTR-CA is further subdivided into wild-type (ATTRwt-CA) and variant (ATTRv-CA) based on the presence or absence of a mutation in the transthyretin gene. CA is significantly underdiagnosed and increasingly recognized as a cause of heart failure with preserved ejection fraction. Advances in diagnosis that employ nuclear scintigraphy to diagnose ATTR-CA without a biopsy and the emergence of effective treatments, including transthyretin stabilizers and silencers, have changed the landscape of this field and render early and accurate diagnosis critical. This review summarizes the epidemiology, pathophysiology, diagnosis, prognosis, and management of CA with an emphasis on the significance of recent developments and suggested future directions.
ドースデンス化学療法は抗腫瘍免疫応答の機序を改善する | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Chang Chih-Long, Hsu Yun-Ting, WU Chao-Chih, Lai Yan-Zen, Wang Connie, Yang Yuh-Cheng, Wu T.-C., Hung Chien-Fu
Journal: Cancer Research (2013)
Decreasing Medicare Spending on Prescription Drugs
Authors: Robert Steinbrook
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 16846: Hemodynamic Effects of alpha-Adrenergic Blockade With Phentolamine Following Stage One Palliation of Hypoplastic Left Heart Syndrome
Authors: George M Hoffman, Kathleen A Mussatto, James S Tweddell, Nancy S Ghanayem
Journal: Circulation (2013)

Background: We used phenoxybenzamine (PBZ) with an FDA-approved IND to reduce systemic afterload and improve systemic oxygenation in patients with hypoplastic left heart syndrome (HLHS) after stage...
Author Correction: A human ciliopathy reveals essential functions for NEK10 in airway mucociliary clearance
Authors: Raghu R. Chivukula, Daniel T. Montoro, Hui Min Leung, Jason Yang, Hanan E. Shamseldin, Martin S. Taylor, Gerard W. Dougherty, Maimoona A. Zariwala, Johnny Carson, M. Leigh Anne Daniels, Patrick R. Sears, Katharine E. Black, Lida P. Hariri, Ibrahim Almogarri, Evgeni M. Frenkel, Vladimir Vinarsky, Heymut Omran, Michael R. Knowles, Guillermo J. Tearney, Fowzan S. Alkuraya, David M. Sabatini
Journal: Nature Medicine (2020)
An Atlas of Human Anatomy. For Students and Physicians.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 369: Implantable Cardioverter Defibrillator Therapy in Patients With Vasospastic Angina After Sudden Cardiac Arrest
Authors: Kazuya Tateishi, Yusuke Kondo, Hideki Kitahara, Masahiro Nakano, Takashi Nakayama, Yoshihide Fujimoto, Yoshio Kobayashi
Journal: Circulation (2019)

Introduction: The prognosis of vasospastic angina (VSA) treated with optimal medication therapy is generally good. However, the patients resuscitated from sudden cardiac arrest (SCA) caused by lethal ventricular arrhythmias are at high risk of recurrent cardiovascular events. Moreover, little is known about the efficacy of implantable cardioverter defibrillator (ICD) therapy in this population The aim of this study is to evaluate the incidence of lethal arrhythmic events in VSA patients with secondary prophylaxis for SCA. Methods: Data from patients who received an ICD as a secondary prophylaxis in our institution between January 2012 and November 2018 were retrospectively analyzed. A total of 123 patients were enrolled in this study and divided into 16 patients with VSA (VSA group) and 107 patients without VSA (non-VSA group). VSA was diagnosed by acetylcholine provocation test or coronary angiography alone on arrival. Results: Current smoker was more prevalent and cardiac function was better in the VSA group. Diabetes mellitus was more prevalent in the non-VSA group. Although VSA patients were treated with calcium-channel blockers, with or without nitrates, 3 patients (18.8%) experienced appropriate ICD therapies due to lethal arrhythmias during a follow-up of 3.2 years. There were no significant differences in the proportion of appropriate and inappropriate therapy between 2 groups. (Table) Conclusions: Recurrent lethal arrhythmic events were common in patients with VSA after SCA. In addition to optimal medical therapy, ICD therapy should be aggressively considered in patients with VSA and a history of lethal arrhythmia.
HHS Provides Free PrEP Medication to People Without Drug Coverage
Authors: Rita Rubin
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction to: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
Authors: Hamzah Abu-Sbeih, Lauren Nicholas Herrera, Tenglong Tang, Mehmet Altan, Anne-Marie Chaftari, Pablo C. Okhuysen, Robert R. Jenq, Yinghong Wang
Journal: Journal for ImmunoTherapy of Cancer (2019)

Following publication of the original article [1], the authors have reported that an author's name has been incorrectly spelled: the correct given name is Anne-Marie (instead of Anne-Maria P) and family name is Chaftari.
Surface-modified GVs as nanosized contrast agents for molecular ultrasound imaging of tumor
Authors: Guohao Wang, Lin Song, Xuandi Hou, Shashwati Kala, Kin Fung Wong, Liya Tang, Yunlu Dai, Lei Sun
Journal: Biomaterials (2020)

Nanobubbles, as a kind of new ultrasound contrast agent (UCAs), have shown promise to penetrate tumor vasculature to allow for targeted imaging. However, their inherent physical instability is an ongoing concern that could weaken their imaging ability with ultrasound. Gas vesicles (GVs), which are genetically encoded, naturally stable nanostructures, have been developed as the first ultrasonic biomolecular reporters which showed strong contrast enhancement. However, further development of tumor imaging with GVs is limited by the quick clearance of GVs by the reticuloendothelial system (RES). Here, we developed PEGylated HA-GVs (PH-GVs) for in-tumor molecular ultrasound imaging by integrating polyethylene glycol (PEG) and hyaluronic acid (HA) in GV shells. PH-GVs were observed to accumulate around CD44-positive cells (SCC7) but not be internalized by macrophage cell line RAW 264.7. Green fluorescence from PH-GVs was found around cell nuclei in the tumor site after 6 h and the signal was sustained over 48 h following tail injection, demonstrating PH-GVs' ability to escape the clearance from the RES and to penetrate tumor vasculature through enhanced permeability and retention (EPR) effects. Further, PH-GVs produced strong ultrasound contrast in the tumor site in vivo, with no obvious side-effects detected following intravenous injection. Thus, we demonstrate the potential of PH-GVs as novel, nanosized and targeted UCAs for efficient and specific molecular tumor imaging, paving the way for the application of GVs in precise and personalized medicine.
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Authors: Neesha C. Dhani, Hal W. Hirte, Lisa Wang, Julia V. Burnier, Angela Jain, Marcus O. Butler, Stephen Welch, Gini F. Fleming, Jean Hurteau, Koji Matsuo, Daniela Matei, Waldo Jimenez, Carolyn Johnston, Mihaela Cristea, Katia Tonkin, Prafull Ghatage, Stephanie Lheureux, Anjali Mehta, Judy Quintos, Qian Tan, Suzanne Kamel-Reid, Olga Ludkovski, Ming-Sound Tsao, John J. Wright, Amit M. Oza
Journal: Clinical Cancer Research (2020)

The relevance of the MET/hepatocyte growth factor pathway in endometrial cancer tumor biology supports the clinical evaluation of cabozantinib in this disease.PHL86/NCI#9322 (NCT01935934) is a single arm study that evaluated cabozantinib (60 mg once daily) in women with endometrial cancer with progression after chemotherapy. Coprimary endpoints were response rate and 12-week progression-free-survival (PFS). Patients with uncommon histology endometrial cancer (eg, carcinosarcoma and clear cell) were enrolled in a parallel exploratory cohort.A total of 102 patients were accrued. Among 36 endometrioid histology patients, response rate was 14%, 12-week PFS rate was 67%, and median PFS was 4.8 months. In serous cohort of 34 patients, response rate was 12%, 12-week PFS was 56%, and median PFS was 4.0 months. In a separate cohort of 32 patients with uncommon histology endometrial cancer (including carcinosarcoma), response rate was 6% and 12-week PFS was 47%. Six patients were on treatment for >12 months, including two for >30 months. Common cabozantinib-related toxicities (>30% patients) included hypertension, fatigue, diarrhea, nausea, and hand-foot syndrome. Gastrointestinal fistula/perforation occurred in four of 70 (6%) patients with serous/endometrioid cancer and five of 32 (16%) patients in exploratory cohort. We observed increased frequency of responses with somatic CTNNB1 mutation [four partial responses (PRs) in 10 patients, median PFS 7.6 months] and concurrent KRAS and PTEN/PIK3CA mutations (three PRs in 12 patients, median PFS 5.9 months).Cabozantinib has activity in serous and endometrioid histology endometrial cancer. These results support further evaluation in genomically characterized patient cohorts.
A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes
Authors: Melissa Azoulay, Steven D Chang, Iris C Gibbs, Steven L Hancock, Erqi L Pollom, Griffith R Harsh, John R Adler, Ciara Harraher, Gordon Li, Melanie Hayden Gephart, Seema Nagpal, Reena P Thomas, Lawrence D Recht, Lisa R Jacobs, Leslie A Modlin, Jacob Wynne, Kira Seiger, Dylann Fujimoto, Melissa Usoz, Rie von Eyben, Clara Y H Choi, Scott G Soltys
Journal: Neuro-Oncology (2020)

Abstract Background We sought to determine the maximum tolerated dose (MTD) of 5-fraction stereotactic radiosurgery (SRS) with 5-mm margins delivered with concurrent temozolomide in newly diagnosed glioblastoma (GBM). Methods We enrolled adult patients with newly diagnosed glioblastoma to 5 days of SRS in a 3 + 3 design on 4 escalating dose levels: 25, 30, 35, and 40 Gy. Dose limiting toxicity (DLT) was defined as Common Terminology Criteria for Adverse Events grades 3–5 acute or late CNS toxicity, including adverse radiation effect (ARE), the imaging correlate of radiation necrosis. Results From 2010 to 2015, thirty patients were enrolled. The median age was 66 years (range, 51–86 y). The median target volume was 60 cm3 (range, 14.7–137.3 cm3). DLT occurred in 2 patients: one for posttreatment cerebral edema and progressive disease at 3 weeks (grade 4, dose 40 Gy); another patient died 1.5 weeks following SRS from postoperative complications (grade 5, dose 40 Gy). Late grades 1–2 ARE occurred in 8 patients at a median of 7.6 months (range 3.2–12.6 mo). No grades 3–5 ARE occurred. With a median follow-up of 13.8 months (range 1.7–64.4 mo), the median survival times were: progression-free survival, 8.2 months (95% CI: 4.6–10.5); overall survival, 14.8 months (95% CI: 10.9–19.9); O6-methylguanine-DNA methyltransferase hypermethylated, 19.9 months (95% CI: 10.5–33.5) versus 11.3 months (95% CI: 8.9–17.6) for no/unknown hypermethylation (P = 0.03), and 27.2 months (95% CI: 11.2–48.3) if late ARE occurred versus 11.7 months (95% CI: 8.9–17.6) for no ARE (P = 0.08). Conclusions The per-protocol MTD of 5-fraction SRS with 5-mm margins with concurrent temozolomide was 40 Gy in 5 fractions. ARE was limited to grades 1–2 and did not statistically impact survival.
Clearing the Air — A Conservative Option for Spontaneous Pneumothorax
Authors: V. Courtney Broaddus
Journal: New England Journal of Medicine (2020)

For the patient who presents with a large primary pneumothorax (i.e., a pneumothorax with no clear underlying lung disease), there is little evidence to guide management.1 There is general agreement that the air in the pleural space should be removed. If any disagreement exists, it has been about how best to remove it. The British Thoracic Society guidelines advise using a needle to aspirate the pneumothorax and if not successful to place a chest tube2; the American College of Chest Physicians guidelines dispense with the needle and recommend chest-tube placement.3 And yet, whether the intervention, along with the added pain . . .